(12) **Translation of European patent specification**

(11) **NO/EP 3481844 B1**

NORWAY

(19) NO

(51) Int Cl.

C07J 1/00 (2006.01)
A61K 31/57 (2006.01)
A61K 31/58 (2006.01)
A61P 25/00 (2006.01)
C07J 7/00 (2006.01)
C07J 43/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.07.22
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.04.17
(86)	European Application Nr.	17743137.6
(86)	European Filing Date	2017.07.11
(87)	The European Application's Publication Date	2019.05.15
(30)	Priority	2016.07.11, US, 201662360876 P 2016.07.11, US, 201662360884 P 2016.07.11, US, 201662360887 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Sage Therapeutics, Inc., 215 First Street, Cambridge, MA 02142, USA
(72)	Inventor	ROBICHAUD, Albert, J., 2 Earhart Street 915, Cambridge, MA 02141, USA MARTINEZ BOTELLA, Gabriel, 17 Parmenter Road, Wayland, MA 01778, USA HARRISON, Boyd, L., 9 Wheatston Court, Princeton Junction, NJ 08550, USA SALITURO, Francesco, G., 25 Baker Drive, Marlborough, MA 01752, USA GRIFFIN, Andrew, 232 Rue Barrette, L'Ile Bizard, Quebec H9C2Y, Canada BLANCO-PILLADO, Maria Jesus, 72 Thesda Street, Arlington, MA 02474, USA
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, C. J. Hambros plass 2, 0164 OSLO, Norge

(54) Title **C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE**

(56) References Cited:

US-A1- 2016 108 080
WO-A2-2010/003391
WO-A1-2015/180679
WO-A1-98/05337
BARBORA SLAVÍKOVÁ ET AL: "Allopregnanolone (3[alpha]-Hydroxy-5[alpha]-pregnan-20-one) Derivatives with a Polar Chain in Position 16[alpha]: Synthesis and Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 7, 9 April 2009 (2009-04-09), pages 2119-2125, XP055406982, ISSN: 0022-2623, DOI: 10.1021/jm801454a

STASTNA E ET AL: "Synthesis of C3, C5, and C7 pregnane derivatives and their effect on NMDA receptor responses in cultured rat hippocampal neurons", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 74, no. 2, 24 November 2008 (2008-11-24), pages 256-263, XP025894826, ISSN: 0039-128X, DOI: 10.1016/J.STEROIDS.2008.11.011 [retrieved on 2008-11-24]
KRAFFT ET AL: "Synthesis of the C/D/E and A/B Rings of Xestobergsterol-(A)", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY ETC.|, vol. 64, no. 7, 18 March 1999 (1999-03-18) , pages 2475-2485, XP002216916, ISSN: 0022-3263, DOI: 10.1021/JO982319W
HANA CHODOUNSKÁ ET AL: "Epalons: Synthesis of 3[alpha],7[alpha]-Dihydroxy-5[alpha]-pregn an-20-one", COLLECTION SYMPOSIUM SERIES (XIIITH SYMPOSIUM ON CHEMISTRY OF NUCLEIC ACID COMPONENTS SPINDLERUV MLYN, CZECH REPUBLIC; SEPTEMBER 03 -09, 2005), vol. 63, no. 10, 1998, pages 1543-1548, XP055406876, XX ISSN: 0010-0765, DOI: 10.1135/cccc19981543 ISBN: 978-80-86241-25-8
PATRICE C PEART ET AL: "Hydroxylation of steroids by,and", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 76, no. 12, 7 July 2011 (2011-07-07), pages 1317-1330, XP028286807, ISSN: 0039-128X, DOI: 10.1016/J.STEROIDS.2011.06.010 [retrieved on 2011-07-07]
Monica E Deluca ET AL: "98. Synthesis of 3P-Hydro~y[Zl-'~C]-5/?-pregn-8(14)-en-20-one from Chenodeoxycholic Acid", , 1986, XP055407089, Retrieved from the Internet: URL:http://onlinelibrary.wiley.com/store/1 0.1002/hlca.19860690810/asset/19860690810_ftp.pdf?v=1&t=j7lpx7ms&s=1fe8c4e128f3e8367 9125527ed5551f9d1640064
LEHMANN G ET AL: "Schweinegallensauren. V. Der Abbau von Hyocholsaure zu Pregnanderivaten. [Swine bile acids. V. Degradation of hyocholic acid into pregnanone derivatives]", JOURNAL FÜR PRAKTISCHE CHEMIE : PRACTICAL APPLICATIONS AND APPLIED CHEMISTRY : COVERING ALL ASPECTS OF APPLIED CHEMISTRY, WILEY, DE, vol. 32, no. 3-4, 1 July 1966 (1966-07-01) , pages 217-224, XP009500206, ISSN: 0021-8383, DOI: 10.1002/PRAC.19660320316 [retrieved on 2004-11-08]
JUNGMANN R ET AL: "7-Keto-5-[beta]-ätiansäure-Derivate. Über Gallensäuren und verwandte Stoffe, 51. Mitteilung [Bile acids and related substances. LI. 7-Oxo-5.beta.-etianic acid derivatives]", HELVETICA CHIMICA ACTA, VERLAG HELVETICA CHIMICA ACTA, CH, vol. 41, no. 5, 1958, pages 1206-1233, XP009500207, ISSN: 0018-019X, DOI: 10.1002/HLCA.19580410507 [retrieved on 2004-10-24]
SLAVIKOVA BARBORA ET AL: "3.ALPHA.-FLUORO ANALOGUES OF ALLOPREGNANOLONE AND THEIR BINDING TO GABAARECEPTORS", COLLECTION SYMPOSIUM SERIES (XIIITH SYMPOSIUM ON CHEMISTRY OF NUCLEIC ACID COMPONENTS SPINDLERUV MLYN, CZECH REPUBLIC; SEPTEMBER 03 -09, 2005); [COLLECTION SYMPOSIUM SERIES / INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY, ACADEMY OF SCIENCES OF THE, vol. 67, no. 1, 1 January 2002 (2002-01-01), pages 30-46, XP008073174, ISSN: 0010-0765, DOI: 10.1135/CCCC20020030 ISBN: 978-80-86241-25-8
PURDY R H ET AL: "Synthesis, Metabolism, and Pharmacological Activity of 3.alpha.-Hydroxy Steroids Which Potentiate GABA-Receptor-Mediated Chloride Ion Uptake in Rat Cerebral Cortical Synaptoneurosomes", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 33, no. 6, 1 January 1990 (1990-01-01), pages 1572-1581, XP002012635, ISSN: 0022-2623, DOI: 10.1021/JM00168A008
BARBORA SLAV?KOV? ET AL: "Allopregnanolone and Pregnanolone Analogues Modified in the C Ring: Synthesis and Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 6, 28 March 2013 (2013-03-28) , pages 2323-2336, XP055406860, US ISSN: 0022-2623, DOI: 10.1021/jm3016365
CRISTINA SUÑOL ET AL: "Activity of B-Nor Analogues of Neurosteroids on the GABA A Receptor in Primary Neuronal Cultures", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 11, 1 June 2006 (2006-06-01), pages 3225-3234, XP055570705, US ISSN: 0022-2623, DOI: 10.1021/jm060002f
ZENG C-M ET AL: "Neurosteroid Analogues. 10. The Effect of Methyl Group Substitution at the C-6 and C-7 Positions on the GABA Modulatory and Anesthetic Actions of (3alpha,5alpha))- and (3alpha,5beta)-3-Hydroxypregnan-20-one", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 48, no. 8, 25 March 2005 (2005-03-25) , pages 3051-3059, XP003021562, ISSN: 0022-2623, DOI: 10.1021/JM049027+

Patentkrav

1. Forbindelse av formel (V):



(V)

eller et farmasøytisk akseptabelt salt derav,

hvori forbindelsen velges fra gruppen som består av:





















eller et farmasøytisk akseptabelt salt av en forbindelse valgt fra gruppen som består av:


N
OH
H
H
H
HO
H
N
O
H
H
H
HO
H
O
O
H
H
H
HO
H









2. Farmasøytisk sammensetning omfattende en forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel eksipiens.

3. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for:
å indusere sedasjon og/eller anestesi hos et menneske, eventuelt hvori

(i) det humane individet opplever sedasjon og/eller anestesi innen to timer etter administrering, eventuelt hvori det humane individet opplever sedasjon og/eller anestesi innen én time etter administrering; eventuelt hvori det humane individet opplever sedasjon og/eller anestesi øyeblikkelig; og/eller
(ii) forbindelsen administreres ved intravenøs administrering; og/eller
(iii) forbindelsen administreres kronisk; og/eller
(iv) forbindelsen administreres i kombinasjon med et annet terapeutisk middel.

4. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for behandling av anfall hos et menneske.

5. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for behandling av epilepsi eller status epilectus hos et menneske.

6. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for behandling av en nevroendokrin forstyrrelse eller dysfunksjon hos et menneske.

7. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for behandling av en nevrodegenerativ sykdom eller forstyrrelse hos et menneske.

8. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for behandling av en bevegelsesforstyrrelse eller skjelving hos et menneske.

9. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for behandling av en stemningsforstyrrelse eller angstforstyrrelse hos et menneske.

10. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse i en fremgangsmåte for behandling av en CNS-relatert forstyrrelse hos et menneske med behov derav.

11. Forbindelse ifølge krav 1 eller en sammensetning ifølge krav 2, for anvendelse ifølge krav 10, hvori den CNS-relaterte forstyrrelsen er en søvnforstyrrelse, en humørforstyrrelse, en schizofrenispektrumforstyrrelse, en krampeforstyrrelse, en forstyrrelse av hukommelse og/eller kognisjon, en bevegelsesforstyrrelse, en personlighetsforstyrrelse, autismespektrumforstyrrelse, smerte, traumatisk hjerneskade, en vaskulær sykdom, en stoffmisbruksforstyrrelse og/eller bortfallssyndrom eller tinnitus; og/eller hvori individet er et individ med Retts syndrom, fragilt X-syndrom eller Angelmans syndrom.